Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Neuralstem Inc 's study shows Neuralstem cells transplanted into brain significantly improve post-stroke symptoms in Rats


Friday, 28 Mar 2014 09:15am EDT 

Neuralstem Inc:Ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in brain experienced functional improvements.Grafts both survived and differentiated into neurons.Findings further validate application of cells for transplantation therapy in ischemic stroke.Research concluded that NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients. 

Company Quote

2.64
 --
18 Dec 2014